IMRT credentialing for prospective trials using institutional virtual phantoms: results of a joint European Organization for the Research and Treatment of Cancer and Radiological Physics Center project

Radiation Oncology

Coen W Hurkmans¹  David S Followill⁵  Raphael Moeckli³  Suzanne Naudy⁶  Vanda Teglas⁴  Christos Melidis⁴  Andrea Molineu⁵  Veronique Vallet³  Damien C Weber² 

[1] Department of Radiation Oncology, Catharina Hospital, Eindhoven, The Netherlands;EORTC QA Strategic Committee-ROG, Brussels, Belgium;Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland;EORTC Headquarter QA team, Brussels, Belgium;Department of Radiation Physics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA;Centre Georges-François-Leclerc, Dijon, France

关键词: Quality assurance;    Anthropomorphic phantom;    Virtual phantom;    Prospective clinical trial;    IMRT credentialing;   

Others  :  802677
DOI  :  10.1186/1748-717X-9-123

 received in 2013-11-29, accepted in 2014-05-02,  发布年份 2014

【 摘 要 】

Background and purpose

Intensity-modulated radiotherapy (IMRT) credentialing for a EORTC study was performed using an anthropomorphic head phantom from the Radiological Physics Center (RPC; RPC_PH). Institutions were retrospectively requested to irradiate their institutional phantom (INST_PH) using the same treatment plan in the framework of a Virtual Phantom Project (VPP) for IMRT credentialing.

Materials and methods

CT data set of the institutional phantom and measured 2D dose matrices were requested from centers and sent to a dedicated secure EORTC uploader. Data from the RPC_PH and INST_PH were thereafter centrally analyzed and inter-compared by the QA team using commercially available software (RIT; ver.5.2; Colorado Springs, USA).

Results

Eighteen institutions participated to the VPP. The measurements of 6 (33%) institutions could not be analyzed centrally. All other centers passed both the VPP and the RPC ±7%/4 mm credentialing criteria. At the 5%/5 mm gamma criteria (90% of pixels passing), 11(92%) as compared to 12 (100%) centers pass the credentialing process with RPC_PH and INST_PH (p = 0.29), respectively. The corresponding pass rate for the 3%/3 mm gamma criteria (90% of pixels passing) was 2 (17%) and 9 (75%; p = 0.01), respectively.

Conclusions

IMRT dosimetry gamma evaluations in a single plane for a H&N prospective trial using the INST_PH measurements showed agreement at the gamma index criteria of ±5%/5 mm (90% of pixels passing) for a small number of VPP measurements. Using more stringent, criteria, the RPC_PH and INST_PH comparison showed disagreement. More data is warranted and urgently required within the framework of prospective studies.

【 授权许可】

   
2014 Weber et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Molineu A, Followill DS, Balter PA, Hanson WF, Gillin MT, Huq MS, Eisbruch A, Ibbott GS: Design and implementation of an anthropomorphic quality assurance phantom for intensity-modulated radiation therapy for the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 2005, 63:577-583.
• [2]Ibbott GS, Followill DS, Molineu HA, Lowenstein JR, Alvarez PE, Roll JE: Challenges in credentialing institutions and participants in advanced technology multi-institutional clinical trials. Int J Radiat Oncol Biol Phys 2008, 71:S71-S75.
• [3]Molineu A, Hernandez N, Nguyen T, Ibbott G, Followill D: Credentialing results from imrt irradiations of an anthropomorphic head and neck phantom. Med Phys 2013, 40:022101.
• [4]Followill DS, Urie M, Galvin JM, Ulin K, Xiao Y, Fitzgerald TJ: Credentialing for participation in clinical trials. Front Oncol 2012, 2:198.
• [5]Ohri N, Shen X, Dicker AP, Doyle LA, Harrison AS, Showalter TN: Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials. J Natl Cancer Inst 2013, 105:387-393.
• [6]Weber DC, Tomsej M, Melidis C, Hurkmans CW: QA makes a clinical trial stronger: evidence-based medicine in radiation therapy. Radiother Oncol 2012, 105(1):4-8.
• [7]Weber DC, Poortmans PM, Hurkmans CW, Aird E, Gulyban A, Fairchild A: Quality assurance for prospective eortc radiation oncology trials: the challenges of advanced technology in a multicenter international setting. Radiother Oncol 2011, 100(1):150-156.
• [8]Depuydt T, Van Esch A, Huyskens DP: A quantitative evaluation of IMRT dose distributions: refinement and clinical assessment of the gamma evaluation. Radiother Oncol 2002, 62:309-319.
• [9]Palta JR: Credentialing of institutions for IMRT in clinical trials. Int J Radiat Oncol Biol Phys 2004, 59:1257-1259. author reply 1259–1261
• [10]Randall ME, Ibbott GS: Intensity-modulated radiation therapy for gynecologic cancers: pitfalls, hazards, and cautions to be considered. Semin Radiat Oncol 2006, 16:138-143.
• [11]Ibbott GS, Hanson WF, O'Meara E, Kuske RR, Arthur D, Rabinovitch R, White J, Wilenzick RM, Harris I, Tailor RC: Dose specification and quality assurance of radiation therapy oncology group protocol 95–17; a cooperative group study of iridium-192 breast implants as sole therapy. Int J Radiat Oncol Biol Phys 2007, 69:1572-1578.
• [12]Fredh A, Scherman JB, Fog LS, Munck af Rosenschold P: Patient QA systems for rotational radiation therapy: a comparative experimental study with intentional errors. Med Phys 2013, 40:031716.
• [13]Urie M, Ulin K, Followill DS, Ibbott GS, Olch A, Palata J, Purdy JA: Results and analysis by QARC of the IMRT benchmark required by the NCI for participation in clinical trials. Med Phys 2004, 31:1915-1916.
• [14]Sakhalkar H, Sterling D, Adamovics J, Ibbott G, Oldham M: Investigation of the feasibility of relative 3D dosimetry in the radiologic physics center head and neck imrt phantom using presage/optical-CT. Med Phys 2009, 36:3371-3377.
• [15]Hurkmans CW, van Lieshout M, Schuring D, van Heumen MJ, Cuijpers JP, Lagerwaard FJ, Widder J, van der Heide UA, Senan S: Quality assurance of 4D-CT scan techniques in multicenter phase III trial of surgery versus stereotactic radiotherapy (radiosurgery or surgery for operable early stage (stage 1a) non-small-cell lung cancer [rosel] study). Int J Radiat Oncol Biol Phys 2011, 80:918-927.